Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) Debt to Equity (2016 - 2017)

Corcept Therapeutics (CORT) has disclosed Debt to Equity for 6 consecutive years, with $0.07 as the latest value for Q2 2017.

  • For Q2 2017, Debt to Equity fell 92.05% year-over-year to $0.07; the TTM value through Jun 2017 reached $0.07, down 92.05%, while the annual FY2016 figure was $0.35, 76.16% down from the prior year.
  • Debt to Equity hit $0.07 in Q2 2017 for Corcept Therapeutics, down from $0.2 in the prior quarter.
  • Across five years, Debt to Equity topped out at $10.15 in Q2 2014 and bottomed at -$26.31 in Q3 2014.
  • Average Debt to Equity over 5 years is -$0.29, with a median of $1.0 recorded in 2013.
  • On a YoY basis, Debt to Equity climbed as much as 1109.01% in 2014 and fell as far as 2437.21% in 2014.
  • Corcept Therapeutics' Debt to Equity stood at $1.67 in 2013, then crashed by 699.5% to -$10.0 in 2014, then soared by 114.86% to $1.49 in 2015, then crashed by 76.16% to $0.35 in 2016, then plummeted by 80.49% to $0.07 in 2017.
  • According to Business Quant data, Debt to Equity over the past three periods came in at $0.07, $0.2, and $0.35 for Q2 2017, Q1 2017, and Q4 2016 respectively.